{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa)

Purpose of Activity

To provide information on anticoagulants and the development of idarucizumab as an antidote for dabigatran.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Recognize features of various anticoagulants.
  2. Examine data from trials of idarucizumab.
Price: $21.95


  • ANCC 2.0 CH / 1.5 APH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223. Your certificate is valid in all states.

Awarded Advanced Pharmacology Hours

Test Code: CNS0915
Published: Sep/Oct 2015
Expires: 9/6/2019
Passing Score: 13/18 (72%)
Authors: Patricia Anne O'Malley, PhD, RN, CNS